The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Nora Schmit(Imperial College London), Peter Winskill(Imperial College London), Alassane Dicko(Ministère de la Santé et de l'Hygiène Publique), Azra C. Ghani(National University of Singapore), Danielle Woods(University of Oxford), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Katerina Rapi(University of Oxford), Hillary M. Topazian(Imperial College London), Fernando Ramos Lopez(University of Oxford), Duncan Bellamy(University of Oxford), Ally Olotu(Ifakara Health Institute), Katie Ewer(University of Oxford), Kelly McCain(Imperial College London), Adrian V. S. Hill(Jenner Institute), Lisa Stockdale(University of Oxford), Giovanni Charles(Imperial College London), Mainga Hamaluba(Universidade Federal do Rio Grande do Sul), Hamtandi Magloire Natama(Centre National de la Recherche Scientifique et Technologique), Samuel Provstgaard-Morys(Serum Institute of India (India)), Marc Christian Tahita(Institut de Recherche en Sciences de la Santé), Massa dit Achille Bonko(Institut de Recherche en Sciences de la Santé), Hermann Sorgho(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Ousmane Traoré(Institut de Recherche en Sciences de la Santé), Mehreen S. Datoo(University of Oxford), Jeremy Aboagye, Aboubakary Sourabié(Institut de Recherche en Sciences de la Santé), M. Athanase Somé(Institut de Recherche en Sciences de la Santé), Jean‐Bosco Ouédraogo(Institut de Recherche en Sciences de la Santé)
Cited by 48
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
|The Lancet|2001|528
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451